The short answer
Before a menopause or perimenopause telehealth visit, track which symptoms you have, when they began, how often they occur, how much they disrupt your life, and how your menstrual pattern has changed. Bring your medical history, every medicine and supplement, prior testing, and your treatment preferences.
The visit should not begin with the assumption that one hormone or one formulation is right for everyone. A clinician may need to distinguish menopause-related symptoms from other causes, discuss hormone and non-hormone options, and decide whether testing or an in-person evaluation is needed.
Build a timeline instead of a vague symptom list
Hot flashes, night sweats, sleep changes, mood symptoms, vaginal or urinary symptoms, changes in sexual comfort, and menstrual changes can affect people differently. Record when each issue began, how often it happens, what seems to trigger it, and what you have already tried.
The ACOG menopause symptom tracker is one example of a structured way to prepare. The goal is not to diagnose yourself; it is to give the clinician enough detail to understand what is changing and what matters most to you.
Describe bleeding and cycle changes precisely
Perimenopause can involve irregular periods, but bleeding patterns still need context. Record the dates, duration, and heaviness of bleeding, whether spotting occurs between periods, and the date of your last period.
Tell the clinician about any bleeding after menopause, possible pregnancy, pelvic symptoms, or sudden change. Some situations require testing or prompt in-person evaluation rather than a routine online discussion.
Bring the history that changes a hormone conversation
A clinician may ask about your uterus and ovaries, prior hysterectomy, pregnancy history, migraines, blood clots, stroke or heart disease, cancers, liver disease, bone health, smoking, blood pressure, and relevant family history. Do not leave out information because it feels unrelated.
List all prescriptions, nonprescription medicines, vitamins, herbs, and compounded products. Treatments can interact, duplicate one another, or change the risk discussion.
Name the problem you most want to solve
Treatment decisions are easier to evaluate when the goal is concrete: fewer disruptive hot flashes, better sleep, relief from vaginal symptoms, or another defined concern. Ask how success would be judged and when the plan would be reassessed.
Menopause care can include hormonal and non-hormonal options. The route, formulation, and combination matter. If you have a uterus, the endometrial effects of systemic estrogen are part of the clinician's decision.
Use current information, not an old argument about hormone therapy
FDA approved labeling changes for several menopausal hormone therapy products in 2026 after re-evaluating how risks were communicated. That does not make every hormone product appropriate for every person or remove the need for individualized benefit-risk discussion.
Ask which exact product is being considered, whether it is FDA-approved or compounded, which risks and contraindications apply to that product and route, and what monitoring or follow-up is expected.
Know what telehealth can and cannot complete
A telehealth visit can support history-taking, shared decision-making, education, and follow-up. It cannot replace every examination, test, image, or urgent evaluation. A careful service should say when online care is insufficient.
Before the visit ends, confirm the next step: whether you need testing, when to follow up, where to send questions, and what symptoms should prompt urgent or in-person care.
Keep these points
- Track symptoms, cycles, and impact over time so the visit can focus on decisions.
- Bring complete medical, medication, reproductive, and family history.
- Ask about the exact product, alternatives, current evidence, follow-up, and situations requiring in-person care.
Sources
- American College of Obstetricians and Gynecologists: Menopause symptom tracker. Accessed September 9, 2026.
- Office on Women's Health: Menopause basics. Accessed September 9, 2026.
- U.S. Food and Drug Administration: 2026 labeling changes to menopausal hormone therapy products. Accessed September 9, 2026.
This guide provides general information. It does not replace care from a licensed clinician or the instructions supplied with a prescription.